CN106177433A - A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati - Google Patents
A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati Download PDFInfo
- Publication number
- CN106177433A CN106177433A CN201510213059.3A CN201510213059A CN106177433A CN 106177433 A CN106177433 A CN 106177433A CN 201510213059 A CN201510213059 A CN 201510213059A CN 106177433 A CN106177433 A CN 106177433A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- fructus
- group
- health composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000036541 health Effects 0.000 title claims abstract description 34
- 241000233779 Cyclocarya paliurus Species 0.000 title claims abstract description 29
- 230000003345 hyperglycaemic effect Effects 0.000 title description 3
- 210000004369 blood Anatomy 0.000 claims abstract description 61
- 239000008280 blood Substances 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 28
- 235000000346 sugar Nutrition 0.000 claims abstract description 22
- 230000036772 blood pressure Effects 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 241001116389 Aloe Species 0.000 claims abstract description 3
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 3
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 3
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 3
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 3
- 239000009636 Huang Qi Substances 0.000 claims abstract description 3
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 3
- 241001506047 Tremella Species 0.000 claims abstract description 3
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 3
- 244000309464 bull Species 0.000 claims abstract description 3
- 235000008434 ginseng Nutrition 0.000 claims abstract description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 241000208340 Araliaceae Species 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- -1 hydroxypropyl methyl Chemical group 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 244000283207 Indigofera tinctoria Species 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 206010012601 diabetes mellitus Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 206010020772 Hypertension Diseases 0.000 description 16
- 235000013305 food Nutrition 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000037396 body weight Effects 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 6
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- 235000021251 pulses Nutrition 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282894 Sus scrofa domesticus Species 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 235000014590 basal diet Nutrition 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 101000637031 Homo sapiens Trafficking protein particle complex subunit 9 Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102100031926 Trafficking protein particle complex subunit 9 Human genes 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical compound O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000233778 Cyclocarya Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001633680 Polygonatum odoratum Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical class CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of health composition containing leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati, wherein the percentage by weight of three can be 1-98%: 1-98%: 1-98%.Described health composition can also comprise the free Folium Mori of choosing, Fructus Lycii, Rhizoma Polygonati, Thallus Laminariae (Thallus Eckloniae), Fructus Mume, Cortex Mori, Radix Ginseng, Radix Notoginseng, Fructus Ligustri Lucidi, Fructus Corni, Rhizoma Chuanxiong, Rhizoma Atractylodis, Radix Scrophulariae, Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Rhodiolae, Radix Panacis Quinquefolii, Aloe, Fructus Schisandrae Chinensis, Radix Ophiopogonis, Radix et Rhizoma Rhei (processed), the Rhizoma Anemarrhenae, Fructus Tribuli, Folium Ginkgo, the Radix Astragali, Herb Gynostemmae Pentaphylli, Fructus Momordicae charantiae, Radix Et Rhizoma Fagopyri Tatarici, Fructus Cucurbitae moschatae, Rhizoma amorphophalli, Herba Apii graveolentis, Stigma Maydis, Tremella, one or more of in the group that Hericium erinaceus (Bull. Ex Fr.) Pers. and Bulbus Allii are formed.Present invention also offers the application in terms of preparing blood sugar lowering, blood pressure lowering or health-care composition for reducing blood fat of the described health composition.The health composition of the present invention, based on natural drug, has no side effect, and has clear curative effect, synergism and substantially and is prone to the advantages such as masses take.
Description
Technical field
The invention belongs to field of health care food, be specifically related to a kind of comprise leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati
Hyperglycemic health care compositions and preparation thereof and purposes.
Background technology
Diabetes (diabetes mellitus, DM) are one group and are drawn by h and E factor interaction
The clinical syndrome risen, due to insulin secretion, definitely or relative deficiency and target tissue cell are to insulin
Sensitivity reduces, and causes the metabolism disorders such as sugar, fat, protein, with hyperglycemia as outstanding feature,
Cause series of clinical manifestations.Diabetes are the endocrine generations having genetic predisposition of a kind of common multi-pathogenesis
Thanking to disorder disease, along with growth in the living standard, its sickness rate, in the trend risen year by year, becomes and continues
The 3rd killer being detrimental to health after cancer, cardiovascular and cerebrovascular disease.According to World Health Organization (WHO)
New data shows, in following 15 years, the diabetics number of China is up to current 4 times,
Whole world diabetics number will be present 2 times.The relevant diabetes stream that China completes for 1997
Row disease is learned investigation problem and show, and whole nation onset diabetes rate rises to 3.2% from 1% in 1980, northern
The sickness rate of Jing Shi is more than 4%, the more seriously morbidity of diabetes in the old people of more than 60 years old
Rate is more than 11%.The current research report display of 2012, China diabetes patient occupies the whole world first.
The most serious in the situation of western developed country diabetes, the U.S. estimates there are about the sugar of more than 16,000,000
Urine patient, accounts for the 6% of population.
" quenching one's thirst " or " diseases due to endogenous heat of ZANG FU organs " category of the diabetes spp traditional Chinese medical science.Diabetes are broadly divided into by modern medicine
Two types a: class is the insulin-dependent (TDDM) of I type, based on inherited genetic factors, mostly occurs
In teenager.The another kind of non-insulin-depending type for II type (NIDDM), because of insulin resistant and pancreas
Island element secretion relative deficiency or delay, cause blood glucose to raise, and course of disease elder may occur in which the complication of diabetes,
It is mainly in and grows up or middle-aged and elderly people.In all diabeticss, 90% is above suffering from type ii diabetes.
At present, the treatment of diabetes is except with going back some orally-taken blood sugar reducing medicines of adapted in addition to insulin, such as: sulfonylurea,
Metformin class, alpha-glucosidase inhibitor, thiazolidone etc..Although western medicine effect comparison is bright
Aobvious, but side effect is big, as easily caused hypoglycemia, lactic acidosis, intestinal discomfort etc..Although insulin is treated
Method and oral antidiabetic drug can greatly reduce the mortality rate of diabetics, but patient can produce multiple concurrently
Disease, some complication more can cause people in fatal position than diabetes itself to a certain extent.Therefore, for sugar
Urine disease, there is no good radical treatment at present.
This disease such as can not get controlling, it will causes severe chronic complication and then disables lethal.Therefore, add
The prophylactico-therapeutic measures of strong diabetes is paid attention to by countries in the world, research prevent and treat diabetes newtype drug and
Health food is the advanced subject of domestic and international association area.Non-medication treatment diabetes have become current doctor
, threpsology, one of the focus of food scientific research.Although the enterprise that lot of domestic and international is big and scientific research machine
Structure, falls over each other to research and develop hypoglycemic medicine or substitute products, but the most all because of expensive, carrier the most not
Preferable, effect unstable or take trouble and not by people's recognition and acceptance.
Additionally, hypertension, hyperlipidemia are also puzzlements people " modern civilization diseases " in recent years, to human body
Healthy is very harmful, similar with diabetes to its difficulty prevented and treated.
Hypertension is a kind of with the abnormal cardiovascular disease rising a height of principal character of arterial pressure.The cause of disease is divided into former
Essential hypertension and secondary hypertension.The former accounts for the 90% of hypertension, referred to as hypertension
(hypertension).Hypertension is defined as by " WHO/ISH guide in 1999 ": do not take anti-high blood
Pressure drug condition under, shrink pressure ＞ 18.7kpa and diastolic pressure ＞ 12.0kpa, and according to blood pressure raise degree,
The quantity of risk factor, the degree of target organ damage and and the clinical setting deposited hypertension is divided into three
Phase: (1) mild hypertension: without organ injury objective condition；(2) moderate hypertension: at least
(left ventricular hypertrophy, arteria retina narrows, and albuminuria and serum creatinine raise, ultrasonic in organ injury performance
Inspection has arteriosclerosis plaque)；(3) severe hypertension: the clinical manifestation (heart strand of organ injury occurs
Bitterly, myocardial infarction, heart failure, transient ischemic attack, apoplexy, hypertensive encephalopathy, retina
Hemorrhage, serum creatinine ＞ 10mmol/L and renal failure, arteriosclerosis obliterans).Primary disease belongs to the traditional Chinese medical science
The category such as " dizziness ", " headache ".
Hyperlipemia (hyperlipemia) also known as hyperlipoproteinemia, can behave as hypercholesterolemia,
Hypertriglyceridemia or both have concurrently, it is with tremulous pulse medicated porridge sample hardening, diabetes, fatty liver, nephropathy
The closest etc. relation.Consequence is especially had day by day to cause people in the morbidity of cardiovascular and cerebrovascular disease
Attention.The traditional Chinese medical science thinks that hyperlipemia belongs to the categories such as " turbid resistance ", " phlegm-damp ", " fat ", " damp and hot ".
Hyperglycemia, hypertension, hyperlipidemia (" three high ") cause of disease are complicated, and the current cause of disease is not completely clear and definite,
Doctor trained in Western medicine it is generally acknowledged its mainly by inherited genetic factors, environmental factors, hyperinsulinemia and insulin resistant,
Obesity, Anomalous lipid metablism etc. influence each other caused.Although the comparitive study of western medical treatment is certainly at present, but
The treatment difficulty being combined disease and complication thereof is relatively big, can cause the side effect that degree is different, patient simultaneously
Often it is difficult to stand, it is impossible to adhere to treatment.The traditional Chinese medical science to the understanding of above-mentioned disease and preventing and treating, is then from entirety
Conditioning, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs are started with, although do not have Western medicine quick, but nursed one's health by entirety, symptom and index
Will be effectively controlled, can effectively protect target organ etc. simultaneously.From clinically, the highest blood
Fat, hyperglycemia, hypertensive patients occur, reciprocal causation.Scientific research proves, slight long-term slow
Property hyperglycemia just can cause the generation of all chronic complicating diseases, and long-term blood pressure increases, and again results in each
Plant the generation of diseases of cardiovascular and cerebrovascular systems.Recently, more result of study confirms, prevent to reach and
Complication is delayed to occur and the purpose of development, it should extremely to emphasize the control of many factors, such as at II
In patients with type Ⅰ DM, in addition to strict glycemic control, blood pressure level, also should take strictly to control blood fat
Level, strictly controls the measures such as body weight, conventional anticoagulant therapy, to reduce the wind of macroangiopathy further
Danger.But the Chinese medicine composition that can prevent or treat " three high " so far is known clearly very few simultaneously, it is possible to
Obtaining satisfied curative effect and the high pharmaceutical composition of patient compliance rarely has report especially, therefore, research is opened
Send out the safely and effectively medicine that can prevent simultaneously and treat " three high ", be the task of top priority, extremely urgent.
In the last few years, from natural product, the new composition having physiologically active or lead compound are found to open
Send out new drug or health food base section has become the focus of global concern and research.Seek blood sugar lowering, blood pressure lowering and fall
Its functional factor is also dissected, and then Development and Production goes out blood sugar lowering, blood pressure lowering, fall by fat food resource
The Material for Health Food of blood fat food is expected to become the good approach treating these diseases.
Cyclocarya paliurus Iljinskaja: (cyclocarya paliurus (Batal.) Ijinsk) belongs to the arbor of Juglandaceae cyclocarya
Plant.The most only deposit one, peculiar for China, it is one of the endangered plants of special-protection-by-the-State, extensively divides
Being distributed in Yangtze river basin each province, Jiangxi Province is northern and hilly and mountainous land distribution in middle part is more.According to " China's book on Chinese herbal medicine "
Record, Cyclocarya paliurus Iljinskaja have dispel the wind, anti-inflammatory analgetic and parasite killing stop the effects such as overworked.Its main component have saponin,
Flavone, terpenoid, polysaccharide, trace element etc..Research shows that leaf of Cyclocarya paliurus Iljinskaja has multiple efficacies, such as blue or green
Money Folium Salicis Babylonicae can substantially suppress lipase active, reduce digesting and assimilating of fat, and can promote lipid material
Metabolic breakdown, can effectively reduce blood glucose, be obviously improved carbohydrate tolerance, antioxidation, resisting fatigue etc..Cyclocarya paliurus Iljinskaja
The exploitation of leaf system row health promoting product, will enrich the health-product market of China, improves the healthy living of the people
Level.
Radix Puerariae: (Puerariae Radix) is the dry root of legume pueraria lobata, practises and claims Herba Gelsemii Elegantis.Autumn,
Season in winter two excavates, sweet in the mouth, pungent, cool in nature.There is expelling pathogenic factors from muscles for reducing heat, rash, promoting the production of body fluid to quench thirst, yang invigorating antidiarrheal
Merit, be usually used in exterior syndrome heating, stiff nape and back, measles without adequate eruption, calentura is thirsty, the deficiency of YIN is quenched one's thirst, diarrhea of heat type
Hematodiarrhoea and diarrhea due to hypofunction of the spleen.Modern pharmacology research shows, Radix Puerariae has dilating coronary blood vessel and improves the heart
Myocardial ischemia anaerobic condition, blood pressure lowering, blood sugar lowering, suppression platelet aggregation beta-receptor block, improve brain blood
The effects such as circulation.
Rhizoma Polygonati Odorati: (Polygonatum odoratum (Mill.) Druce), for Liliaceae herbaceos perennial.
Originate in In Southwest China, but wild distribution is the widest.Cold-resistant, the most resistance to the moon, like wet environment, suitably give birth to
It is longer than the chesson abundant containing humus." stem is tetanic, like bamboo arrow shaft, has for Collective Notes to the Canon of Materia medica cloud
Joint ", therefore have the name of Rhizoma Polygonati Odorati.The rhizome of plant can hyoscine.Rhizoma Polygonati Odorati tool yin nourishing, moisturize, heat clearing away, life
The effect such as Tianjin, cough-relieving, can be used as tonic, cures mainly consumption of YIN caused by febrile disease, deficiency-heat cough caused by dryness, heart disease, sugar
The diseases such as urine disease, tuberculosis, and high-grade nourishing food, delicacies and beverage can be made, with health role.
Although producing at present and there is the medicine of function of polysaccharide and substitute products are of a great variety, but have fall blood concurrently
The health product mainly comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati of sugar, blood pressure lowering and hypolipemic function are the most not
Appear in the newspapers.
Summary of the invention
The present inventor, through extensively collecting exploration blood sugar lowering proved recipe among the people, in immense medicine food raw material, passes through
Long-term research and practice, obtain unexpectedly one have concurrently blood sugar lowering, blood pressure lowering and hypolipemic function,
Comprise the health composition of leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati, thus overcome on present in prior art
State defect.
According to an aspect of the invention, it is provided a kind of health care comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati
Compositions, wherein the percentage by weight of leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati is 1-98%:1-98%:1-98%.
In one embodiment of the invention, the percentage by weight of leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati is
10-80%:10-80%:10-80%.
Preferably, the percentage by weight of leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati is 20-60%:20-60%:
20-60%.
It is further preferred that the percentage by weight of leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati is 35%:35%:30%.
In yet another embodiment of the present invention, above-mentioned health composition also can comprise the free Fructus Lycii of choosing
Son, Rhizoma Polygonati, Thallus Laminariae (Thallus Eckloniae), Fructus Mume, Cortex Mori, Radix Ginseng, Radix Notoginseng, Fructus Ligustri Lucidi, Fructus Corni, Rhizoma Chuanxiong, grey
Art, Radix Scrophulariae, Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Rhodiolae, Radix Panacis Quinquefolii, Aloe, Fructus Schisandrae Chinensis, Radix Ophiopogonis,
Radix et Rhizoma Rhei (processed), the Rhizoma Anemarrhenae, Fructus Tribuli, Folium Ginkgo, the Radix Astragali, Herb Gynostemmae Pentaphylli, Fructus Momordicae charantiae, Radix Et Rhizoma Fagopyri Tatarici, Fructus Cucurbitae moschatae, Rhizoma amorphophalli,
One or more of in the group that Herba Apii graveolentis, Stigma Maydis, Tremella, Hericium erinaceus (Bull. Ex Fr.) Pers. and Bulbus Allii are formed.
In the present invention, described health composition can be carried out by the preparation method of any routine in this area
Preparation.
According to another aspect of the present invention, it is provided that described health composition is preparing blood sugar lowering, fall blood
Application in terms of pressure or health-care composition for reducing blood fat.
According to a further aspect of the invention, it is provided that a kind of medicine system containing described health composition
Agent.
The health composition of the present invention can be prepared as any with pharmaceutically acceptable adjuvant as required
Suitably oral formulations is for blood sugar lowering, blood pressure lowering or blood fat reducing.
In yet other embodiments, described oral formulations can be tablet, capsule,
The dosage forms such as granule, powder, effervescent, bagged steeping drug.
In yet other embodiments, described pharmaceutically acceptable adjuvant such as can select
From pregelatinized Starch, beta-schardinger dextrin-, carbomer, microcrystalline Cellulose, hydroxypropyl methyl cellulose, low take
For hydroxypropyl cellulose, Polyethylene Glycol (PEG), sodium carboxymethyl cellulose, methylcellulose, ethyl
Cellulose, mannitol, cross-linking sodium carboxymethyl cellulose, lactose, polyvinylpyrrolidone (PVP),
One in magnesium stearate, Pulvis Talci, micropowder silica gel, aspartame, sodium bicarbonate, sodium carbonate or more
Multiple.
Effect activity of each primary raw material medicine in the present invention
Leaf of Cyclocarya paliurus Iljinskaja: mildly bitter flavor, pungent, property is put down.Have invigorating the spleen for eliminating dampness, Clearing heat and removing obstruction of fu-organs, depressed liver-energy dispersing and QI regulating,
The effect of enriching yin and nourishing kidney, to because dysfunction of the spleen, expectorant are turbid, addiction delicious food savoury, lazy dynamic, abdominal distention food stagnation,
The liver silt stagnation of QI and the obesity that causes, have good improvement.
Radix Puerariae: sweet in the mouth, pungent, cool in nature.Attach to the lung and stomach meridians.Have expelling pathogenic factors from muscles for reducing heat, rash, promoting the production of body fluid to quench thirst,
Effect of yang invigorating antidiarrheal, the deficiency of YIN thirsty for exterior syndrome heating, stiff nape and back, measles without adequate eruption, calentura disappears
Yearningly, the disease such as diarrhea of heat type hematodiarrhoea, diarrhea due to hypofunction of the spleen.
Rhizoma Polygonati Odorati: yin nourishing, moisturize, heat clearing away, promote the production of body fluid, cough-relieving, can be used as tonic, cure mainly calentura wound
The disease such as the moon, deficiency-heat cough caused by dryness, heart disease, diabetes, tuberculosis.
Technical scheme has the advantage that
The health composition of the present invention, based on natural drug, has no side effect, and makes patient at normal drink
In the case of food, consciously safeguard glucostasis, it is thus achieved that the non-drug therapy effect of diabetes；
The present invention is additionally contemplates that when preparing health composition the nutritive equilibrium of diabetics and metabolism are asked
Topic, is simultaneously applicable to hypertension and the prevention of hyperlipemic patients and treatment.
Detailed description of the invention
To further describe the present invention below in detail.It is pointed out that following description is only to this
The illustration of the technical scheme that invention is claimed, the not any restriction to these technical schemes.This
The content that the protection domain of invention is recorded with appended claims is as the criterion.
Embodiment 1
Formula forms: leaf of Cyclocarya paliurus Iljinskaja 1.0kg, Radix Puerariae 8.0kg, Rhizoma Polygonati Odorati 1.0kg.
Preparation method:
2.1 accurately weigh each taste Chinese medicine according to above-mentioned formula, clean by clean water, boil extraction 2 times；
For the first time add 12 times amount water, extracts 2 hours, add 10 times amount water for the second time, extract 1 hour, 100
Mesh filters；
2.2 united extraction liquid, filter, and filtrate is concentrated into 60 DEG C of heat and surveys relative density 1.05-1.08, standby；
2.3 filtrate is added in spray dryer, first preheating tower temperature, treat that inlet temperature reaches 210 DEG C ± 10
Charging is started after DEG C；The regulation of flow to be carried out, wind speed after charging, leaving air temp is controlled 95 DEG C ±
5 DEG C, obtain extract powder, seal powder with double-deck clean plastic bag packaging；
2.4 by extract powder and mannitol, mixes 3-5 minute；
2.5 by mixed material with 70% edible ethanol moistening soft material, cross 20 mesh, obtain wet granular, wet
Grain dries to obtain dry granule；
2.6 with 20 mesh and 60 eye mesh screen granulate, take less than 20 mesh and are more than the 60 dry granules of purpose by 3g/
Bag carries out subpackage, to obtain final product.
Embodiment 2
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 2.0kg, Radix Puerariae 1.0kg, Rhizoma Polygonati Odorati 7.0kg.
2, preparation method: with embodiment 1.
Embodiment 3
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 3.5kg, Radix Puerariae 3.5kg, Rhizoma Polygonati Odorati 3.0kg.
2, preparation method: with embodiment 1.
Embodiment 4
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 6.0kg, Radix Puerariae 2.0kg, Rhizoma Polygonati Odorati 2.0kg.
2, preparation method: with embodiment 1.
Embodiment 5
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 8.0kg, Radix Puerariae 1.0kg, Rhizoma Polygonati Odorati 1.0kg.
2, preparation method: with embodiment 1.
Embodiment 6
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 1.0kg, Rhizoma Polygonati Odorati 1.0kg, Rhizoma Dioscoreae 1.0kg, Fructus Lycii 1.0kg,
Radix Rhodiolae 1.0kg, Radix Ophiopogonis 1.0kg, Radix et Rhizoma Rhei (processed) 1.0kg, Fructus Schisandrae Chinensis 1.0kg, Rhizoma amorphophalli 1.0kg, monkey
Head mushroom 1.0kg.
2, preparation method: with embodiment 1.
Comparative example 1
Choose the sample as a comparison case 1 that leaf of Cyclocarya paliurus Iljinskaja 10kg is prepared by the preparation method in embodiment 1.
Comparative example 2
Choose the sample as a comparison case 2 that Radix Puerariae 10kg is prepared by the preparation method in embodiment 1.
Comparative example 3
Choose the sample as a comparison case 3 that Rhizoma Polygonati Odorati 10kg is prepared by the preparation method in embodiment 1.
The scope of the present invention is not limited to above example, and each component in above-described embodiment is all selected from
Commercial goods, by the preparation process that this area is conventional, can make multiple dosage form described on pharmaceutics,
Such as capsule, granule, powder, tablet, oral liquid, the bag bubble bitter edible plant etc..
Experimental example 1: blood sugar lowering is tested
1, material and method
1.1 samples and reagent: sample prepared by embodiment 1-6 and comparative example 1-3, be respectively designated as S1,
S2, S3, S4, S5, S6, and D1, D2, D3；Streptozotocin, SIGMA Products,
Specification: 1g/ props up, lot number: SLBJ7785V；Detection kit for insulin, import subpackage, Nanjing is built up
Bio-engineering corporation, 20141022；The sodium chloride injection (normal saline) of 0.9%, specification: 250ml/
Bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；High lipid food formula (79%
Basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica), picric acid etc..
1.2 instrument W-80A eddy mixers, Instrument Factory of Shanghai Medical Univ.'s product；Electronic balance, mettler
Toledo, made by mettler-toledo group, model: p1303；LDZ5-2 centrifuge, north
Jing Yiyonglixinjichang；Johnson & Johnson surely person of outstanding talent's blood glucose meter (Johnson & Johnson (Chinese) medical device company limited)；
BECKMAN Synchron CX5 fully automatic blood biochemistry analyzer (U.S.)；Microplate reader, bio-rad
(U.S.), model: iMark；DCA2000 type glycolated hemoglobin analysis, public for Bayer Bitterfeld GmbH
Department's product；Other: platform balance, fixing cage etc..
1.3 laboratory animal SPF level SD rats, body weight 160～180g, male, big by south medical courses in general
Experimental Animal Center provides, the quality certification number: SCXK (Guangdong) 2011-0015.Animal is in SPF level barrier
Level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviationRepresenting, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
2.1 method
2.1.1 rat feed normal diet: Semen Maydis powder 80%, flour 15%, analysis for soybean powder 5%；High fat
Feedstuff: 79% basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica.
2.1.2 modeling: take 160-180gSPF level SD rat 110, male, body weight 160～180g,
Adaptability takes 10 after feeding one week and is only used as Normal group, feeds with chow diet, and other respectively organizes elder generation
Feed 1 month with high lipid food, after selective examination blood lipids index is significantly raised, lumbar injection STZ 35mg/kg
(STZ is before use by the citric acid/sodium citrate buffering of 0.1mmol/LpH=4.5 for induced Diabetic model
Liquid is made into the solution of 6mg/mL, and is finished in 60min).7d after injection, docking gathers sky
Abdomen venous blood, measures blood glucose with blood glucose meter, is considered as being modeled as more than or equal to 16.7mmol/L by blood glucose value
Merit.After model stability, according to blood-fat and blood sugar height packet, it is orally administered to test medicine and control drug,
Observe indices.
2.1.3 it is grouped and is administered: preferable 100 the modeling success animals of state of choosing are according to blood glucose value and body
Weight average is even is divided into 10 groups: often group 10, i.e. type ii diabetes model control group (giving distilled water),
S1 group, S2 group, S3 group, S4 group, S5 group, S6 group, D1 group, D2 group and D3 group.Normally
The SD rat of not modeling 10 is Normal group (giving distilled water).Each group is administered orally by corresponding dosage
It is administered, is administered once daily, dosage period: 4 weeks (4W).
2.2 testing index
2.2.1 use blood glucose meter respectively measure administration before and be administered after 2W and 4W blood glucose value.
2.2.2 serum insulin, saccharification hemoglobin content are detected.
2.2.4 carbohydrate tolerance test: terminate a few days ago to detect in experiment；Carbohydrate tolerance detects: animal fasting
About 6 hours, each group gave variable concentrations given the test agent, oral administration of glucose 2.0g/kg after 15-20 minute,
Measuring to the blood glucose value of after glucose 0,0.5,2 hours, observing and nursing matched group is given with given the test agent group
The change of each time point Area under the curve of blood glucose after glucose.Area under the curve of blood glucose=1/2 × (0 hour blood
Sugar value+0.5 hours blood glucose value) × 0.5+1/2 × (2 hours blood glucose value+0.5 hours blood glucose value) × 1.5=
0.25 × (0 hours blood glucose value+4 × 0.5 hours blood glucose value+3 × 2 hours blood glucose value).
2.3 result
2.3.1 the impact on type ii diabetes rat blood sugar
From table 1, comparing with Normal group, it is notable that the front Glycemia Decline of administration respectively organizes rat blood sugar
Raise, show diabetes model modeling success.After being administered 2w, compare with model control group, S1-S6
Group and D1 group blood glucose all have decline.After being administered 4w, S1-S6 group and D1 group blood glucose all have decline.
The impact on type ii diabetes rat blood sugar of table 1. sample
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model group: * p ＜ 0.05,
* p ＜ 0.01
2.3.2 on type ii diabetes rat blood serum insulin and the impact of glycolated hemoglobin
From table 2, comparing with Normal group, model control group feeds high lipid food and Glycemia Decline
After, rat blood serum insulin substantially reduces (p ＜ 0.01), glycolated hemoglobin significantly raised (p ＜ 0.01),
Show olive Antihyperlipidemia capsule modeling success.Compare with model control group, S1-S6 group and D1 group serum
Insulin all has increase.Compare with model control group, under S1-S6 group and D1 group glycolated hemoglobin all have
Fall (comparing P ＜ 0.05 with model group).
Table 2. sample is on type ii diabetes rat blood serum insulin and the impact of glycolated hemoglobin
| Group | n | Insulin (mmol/L) | Glycolated hemoglobin (mmol/L) |
| Normal group | 10 | 18.42±2.83 | 3.65±0.71 |
| Model control group | 10 | 8.92±2.42## | 9.52±1.41## |
| S1 group | 10 | 12.21±2.35* | 6.96±1.74* |
| S2 group | 10 | 12.52±2.44* | 6.87±1.62* |
| S3 group | 10 | 13.41±1.83** | 6.42±1.28** |
| S4 group | 10 | 12.40±2.26* | 7.01±1.36* |
| S5 group | 10 | 12.58±2.19* | 7.10±1.45* |
| S6 group | 10 | 12.69±2.17* | 6.99±1.29* |
| D1 group | 10 | 12.15±2.11* | 6.95±1.35* |
| D2 group | 10 | 9.87±2.74 | 8.63±2.31 |
| D3 group | 10 | 9.90±2.85 | 8.54±2.06 |
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model group: * p ＜ 0.05,
* p ＜ 0.01
2.3.3 to type ii diabetes rat carbohydrate tolerance test result
From table 3, comparing with model control group, the Area under the curve of blood glucose of S1-S6 group and D1 group is equal
There is decline.
Table 3. sample is to type ii diabetes rat carbohydrate tolerance test result
| Group | n | Area under the curve of blood glucose |
| Normal group | 10 | 12.14±0.95 |
| Model control group | 10 | 38.60±6.45## |
| S1 group | 10 | 30.22±6.15* |
| S2 group | 10 | 31.57±6.48* |
| S3 group | 10 | 27.94±5.78** |
| S4 group | 10 | 28.89±6.76* |
| S5 group | 10 | 30.81±6.19* |
| S6 group | 10 | 31.30±5.74* |
| D1 group | 10 | 30.44±6.86* |
| D2 group | 10 | 35.47±5.97 |
| D3 group | 10 | 36.83±6.40 |
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model control group: p is equal
More than 0.05.
3. conclusion: S1-S6 and D1 has obvious hypoglycemic activity, and S1-S6 to diabetic model rats
Compositions in terms of blood sugar lowering, create significant synergy.
Experimental example 2: lipid-lowering test
1, material and method
1.1 medicines and reagent: sample prepared by embodiment 1-6 and comparative example 1-3, be respectively designated as S1,
S2, S3, S4, S5, S6, and D1, D2, D3；The sodium chloride injection (normal saline) of 0.9%,
Specification: 250ml/ bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；High fat is raised
Material formula (79% basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica), distilled water, picric acid,
Deng.
1.2 instrument W-80A eddy mixers, Instrument Factory of Shanghai Medical Univ.'s product；Electronic balance, mettler
Toledo, made by mettler-toledo group, model: p1303；LDZ5-2 centrifuge, north
Jing Yiyonglixinjichang；BECKMAN Synchron CX5 fully automatic blood biochemistry analyzer is (beautiful
State)；Other: platform balance, fixing cage etc..
1.3 laboratory animal SPF level SD rats, body weight 160～180g, male, big by south medical courses in general
Experimental Animal Center provides, the quality certification number: SCXK (Guangdong) 2011-0015.Animal is in SPF level barrier
Level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviation (x ± s) represents, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
2.1 packets take SPF level SD rat 110 with method, male, and body weight 160～180g is suitable
Answering property takes 10 after feeding one week and is only used as Normal group, feeds with chow diet；Residue gives high fat
Forage feed.Continuous nursing 4 weeks (determining that modeling is the most successful by timing blood drawing detection four items of blood lipid tests)
After, preferable 100 the modeling success animals of state of choosing uniformly are divided into 10 according to blood fat numerical value and body weight
Group: often group 10, i.e. hyperlipemia model matched group (giving distilled water), S1 group, S2 group, S3
Group, S4 group, S5 group, S6 group, D1 group, D2 group and D3 group.
High lipid food is started to be administered and continue (just feeding high lipid food by above packet situation after feeding 4 weeks
Often matched group feeds normal diet), every day 1 time, successive administration 4w.After last is administered, fasting overnight,
After next day weighs in, chloral hydrate anesthesia, put to death after postcava blood sampling.Take supernatant after Li Xin to survey
Biochemical indicator in serum.
2.2 Testing index:
(1) general status is observed, and records body weight weekly.
(2) each group rat blood serum lipid index: orbital venous plexus takes blood every two weeks, separation Virus monitory:
T-CHOL (TC), triglyceride (TG), high density lipoprotein (HDL-C), low density lipoprotein, LDL
(LDL-C)。
2.3 result
2.3.1 on the impact of TC, TG, HDL-C, LDL-C in serum
Iipid data in rat blood serum after table 4. modeling success even group-division
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model control group: p is equal
More than 0.05.
Table 5. is each after being administered 4W organizes Iipid data in rat blood serum
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model group: * p ＜ 0.05,
* p ＜ 0.01
From table 4, compare with Normal group, after model control group feeds high lipid food 4W, rat
Serum TC, LDL-C significantly raise (p ＜ 0.01), TG significantly raised (p ＜ 0.05), show hyperlipemia
Disease rat model modeling success.4 groups uniformly it are divided into according to blood lipid level.
From table 5, after being administered 4W, comparing with model control group, S1-S6 group and D1 group can reduce
TC, TG, LDL-C level (p ＜ 0.05 or p ＜ 0.01) in serum.
3. conclusion: S1-S6 and D1 has obvious effect for reducing blood fat, and S1-S6 to Hyperlipemia model rat
Compositions in terms of blood fat reducing, create significant synergy.
Experimental example 3: blood pressure lowering is tested
1, material and method
1.1 medicines and reagent: sample prepared by embodiment 1-6 and comparative example 1-3, be respectively designated as S1,
S2, S3, S4, S5, S6, and D1, D2, D3；The sodium chloride injection (normal saline) of 0.9%,
Specification: 250ml/ bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；Distilled water,
Picric acid, etc..
1.2 instrument DKB-501A type super constant temperature water tanks, reliable test Instrument Ltd. for Shanghai is gloomy
Product；Constant Temp. Oven, for Changsha medical apparatus and instruments factory product；Powlab/4sp ML125 type without
Wound pressure measuring system (ML125/R NIBP, MLT1199 BPTrans-ducer/Cable Kit), Australia is big
Leah Ai De Instrument Ltd. product；MP120-1 electronic balance, for Shanghai Second Balance Factory
Product.
1.3 laboratory animal SPF level SHR rat, body weight 190～230g, male, logical by Beijing dimension
Li Hua laboratory animal Technology Co., Ltd. provides, the quality certification number: SCXK (capital) 2012-0001.Animal in
SPF level barrier level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081,
SPF level WISTAR male rat, Beijing Vital River Experimental Animals Technology Co., Ltd. provides, real
Testing animal productiong credit number is: SCXK (capital) 2012-0001.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviation (x ± s) represents, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
10 groups are divided at random, often group 10 by male for 9-10 week old spontaneous hypertensive rat (SHR),
I.e. hypertension model matched group (giving distilled water), S1 group, S2 group, S3 group, S4 group, S5 group,
S6 group, D1 group, D2 group and D3 group.Separately take normal WISTAR rat 10 for Normal group
(giving distilled water).Each treated animal gavage respectively gives various dose drug, every day 1 time, is administered 4 altogether
Week.Within 4 weeks, rat tail artery blood is detected with noinvasive arteria caudalis pressure measuring system before being administered and after being administered
Pressure value (shrinks pressure, SAP, mmHg).
Noinvasive tail sleeve method (NIBP): rat is put into rat fixator, exposes rat-tail.Take with infrared
Warmer, temperature is set to 38 DEG C, and after irradiating heating rat-tail about 10min, rat-tail deliquescing, rat-tail is moved
Arteries and veins is fully expanded.Be passed through pressurizeing tail sleeve and being fixed on the root of rat-tail, make rat tail artery with
PowerlabML125/R noinvasive arteria caudalis blood pressure determination is analyzed the pulse transducer of system and is in close contact, with
Time observation system pulse wave, can start when stable pulse wave occurs to measure blood pressure.Treat that animal is pacified
After quiet, select 90～420BPM (rat pressurization shelves) to tail sleeve inflating pressure, it is seen that pulse wave gradually subtracts
Little to disappearing, then tail sleeve starts venting, and Mus set pressure reduces, and when pressure is equal to when shrinking pressure, starts
Pulse wave occur, the pressure value of this point is rat-tail and shrinks pressure.Repeated measure 3 times, averages.Meter
Calculating voltage drop value (drop-out value of blood pressure), before after administration, SAP deducts administration, SAP obtains.The results are shown in Table 6:
The impact to SHR rat blood pressure (SAP, mmHg) of table 6 sample
Note: compare with Normal group: # is P ＜ 0.01；Compare with model control group: * is P ＜ 0.05.
Result shows, compares with Normal group, and model control group rat blood pressure significantly raises, it is seen that from
The success of Essential hypertension rat model.Can show at administration 4W with model control group, S1-S6 group and D1 group
Write the blood pressure (P ＜ 0.05) reducing SHR rat.
3. conclusion: S1-S6 and D1 sample has significant hypotensive activity, and the compositions of S1-S6 exists
Blood pressure lowering aspect creates significant synergy.
Present invention merely illustrates some claimed specific embodiments, one of them or
Technical characteristic described in more technical schemes can be with arbitrary one or more technical scheme phases
Combination, these are combined and the technical scheme that obtains also in the application protection domain, just as these are through group
As the technical scheme closed and obtain specifically is recorded in the disclosure of invention.
Claims (10)
1. a health composition, it comprises leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati.
Health composition the most according to claim 1, wherein leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati
Percentage by weight be 1-98%:1-98%:1-98%.
Health composition the most according to claim 1 and 2, wherein leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and
The percentage by weight of Rhizoma Polygonati Odorati is 10-80%:10-80%:10-80%.
4. according to the health composition described in any one of claim 1-3, wherein leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae
It is 20-60%:20-60%:20-60% with the percentage by weight of Rhizoma Polygonati Odorati.
5. according to the health composition described in any one of claim 1-4, wherein leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae
It is 35%:35%:30% with the percentage by weight of Rhizoma Polygonati Odorati.
6. according to the health composition described in any one of claim 1-5, wherein said health composition
In also comprise choosing free Folium Mori, Fructus Lycii, Rhizoma Polygonati, Thallus Laminariae (Thallus Eckloniae), Fructus Mume, Cortex Mori, Radix Ginseng, Radix Notoginseng,
Fructus Ligustri Lucidi, Fructus Corni, Rhizoma Chuanxiong, Rhizoma Atractylodis, Radix Scrophulariae, Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Rhodiolae, west
Radix Panacis Quinquefolii, Aloe, Fructus Schisandrae Chinensis, Radix Ophiopogonis, Radix et Rhizoma Rhei (processed), the Rhizoma Anemarrhenae, Fructus Tribuli, Folium Ginkgo, the Radix Astragali, strand
Stock indigo plant, Fructus Momordicae charantiae, Radix Et Rhizoma Fagopyri Tatarici, Fructus Cucurbitae moschatae, Rhizoma amorphophalli, Herba Apii graveolentis, Stigma Maydis, Tremella, Hericium erinaceus (Bull. Ex Fr.) Pers. and Bulbus Allii
One or more of in the group formed.
7. the health composition described in any one of claim 1-6 is preparing blood sugar lowering, blood pressure lowering or fall
Application in blood fat health composition.
8. comprise a pharmaceutical preparation for health composition described in any one of claim 1-6, wherein
Described health composition and pharmaceutically acceptable adjuvant are prepared as oral formulations.
Pharmaceutical preparation the most according to claim 8, wherein said oral formulations is tablet, glue
Wafer, granule, powder, effervescent or bagged steeping drug.
Pharmaceutical preparation the most according to claim 8 or claim 9, wherein said pharmaceutically acceptable
Adjuvant is selected from pregelatinized Starch, beta-schardinger dextrin-, carbomer, microcrystalline Cellulose, hydroxypropyl methyl fiber
Element, low-substituted hydroxypropyl cellulose, Polyethylene Glycol (PEG), sodium carboxymethyl cellulose, methyl are fine
Dimension element, ethyl cellulose, mannitol, cross-linking sodium carboxymethyl cellulose, lactose, polyvinylpyrrolidine
Ketone (PVP), magnesium stearate, Pulvis Talci, micropowder silica gel, aspartame, sodium bicarbonate, carbonic acid
One or more of in sodium.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510213059.3A CN106177433A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati |
| US15/128,835 US20170173101A1 (en) | 2015-04-29 | 2016-04-28 | Tea composition comprising cyclocarya paliurus and preparation method and uses thereof |
| PCT/CN2016/080551 WO2016173511A1 (en) | 2015-04-29 | 2016-04-28 | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof |
| PCT/CN2016/080553 WO2016173512A1 (en) | 2015-04-29 | 2016-04-28 | Tea composition comprising cyclocarya paliurus and preparation methord and uses thereof |
| US15/128,866 US10111923B2 (en) | 2015-04-29 | 2016-04-28 | Compositions comprising Cyclocarya paliurus extract and preparation method and uses thereof |
| US15/128,827 US10413580B2 (en) | 2015-04-29 | 2016-04-28 | Compositions comprising Cyclocarya paliurus extract and preparation method and uses thereof |
| EP16785075.9A EP3139941A4 (en) | 2015-04-29 | 2016-04-28 | Tea composition comprising cyclocarya paliurus and preparation method and uses thereof |
| EP16785076.7A EP3125914B1 (en) | 2015-04-29 | 2016-04-28 | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof |
| EP16785077.5A EP3151843B1 (en) | 2015-04-29 | 2016-04-28 | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof |
| PCT/CN2016/080547 WO2016173509A1 (en) | 2015-04-29 | 2016-04-28 | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510213059.3A CN106177433A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106177433A true CN106177433A (en) | 2016-12-07 |
Family
ID=57458284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510213059.3A Withdrawn CN106177433A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106177433A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107087697A (en) * | 2017-03-29 | 2017-08-25 | 广西凌云县盘古生态产业发展有限公司 | It is a kind of can anti-trioxypurine sleeping type cyclocarya paliurus tea and preparation method thereof |
| CN107280006A (en) * | 2017-06-30 | 2017-10-24 | 武汉市百锐纳思生物科技有限公司 | It is a kind of that there is hypoglycemic, blood fat reducing function composition, beverage and its application |
| CN108851046A (en) * | 2018-06-04 | 2018-11-23 | 湖南百汉原健康中药生物有限公司 | A kind of method of integration of drinking and medicinal herbs traditional Chinese medicine extraction melbine |
| CN110651872A (en) * | 2019-11-09 | 2020-01-07 | 泉州市神草茶业有限责任公司 | Cyclocarya paliurus leaf substitute tea and preparation process thereof |
-
2015
- 2015-04-29 CN CN201510213059.3A patent/CN106177433A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107087697A (en) * | 2017-03-29 | 2017-08-25 | 广西凌云县盘古生态产业发展有限公司 | It is a kind of can anti-trioxypurine sleeping type cyclocarya paliurus tea and preparation method thereof |
| CN107280006A (en) * | 2017-06-30 | 2017-10-24 | 武汉市百锐纳思生物科技有限公司 | It is a kind of that there is hypoglycemic, blood fat reducing function composition, beverage and its application |
| CN108851046A (en) * | 2018-06-04 | 2018-11-23 | 湖南百汉原健康中药生物有限公司 | A kind of method of integration of drinking and medicinal herbs traditional Chinese medicine extraction melbine |
| CN110651872A (en) * | 2019-11-09 | 2020-01-07 | 泉州市神草茶业有限责任公司 | Cyclocarya paliurus leaf substitute tea and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN104435775A (en) | Chinese medicinal health-care spirit and preparation method thereof | |
| CN104147385B (en) | A kind of formula of Chinese medicine for lowering blood pressure preparation and preparation method | |
| CN101274078A (en) | Natural plant extract and preparing method and application of the same | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN106177433A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN106177434A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
| CN104223297B (en) | A kind of schisandra chinensis health-care oral liquid of slow down aging and preparation method thereof | |
| CN106177479A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Rhizoma Polygonati Odorati | |
| CN108498708A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN104107348A (en) | Chinese herbal medicine for blood sugar reducing, and administration method thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN101244157A (en) | Natural plants extract, preparation method and application thereof | |
| CN106666703A (en) | Enzyme composition with liver-protecting function, as well as preparation and preparation method thereof | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN107595954A (en) | A kind of Chinese medicine composition for reducing body fat and treating Central obesity and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161207 |
|
| WW01 | Invention patent application withdrawn after publication |